Data-Gouv-ML/pcri-erc-participations-et-projets-laureats huggingface dataset:
Projet ERC : Intimate Touch (Horizon Europe, appel 2021, Consolidator grants)
Domaine scientifique : Physical Sciences and Engineering
Panel : Computer Science and Informatics
Entité participante : KTH Institut royal de technologie — Pays : Suède — Rôle : PI
Type d'entité : Enseignement supérieur ou secondaire
Financement ERC de l'entité : 1780089.0 €

Intimate Touch will re-conceptualise how technologies use touch to interact with us. Bringing intimacy as a lens on touch inspires us to think about the felt experience of touch, the diversity of places on the body where we will be touched by technology, and the sense that touch can be transformative of our view of ourselves. This project will develop the theory, methods and technologies of Intimate Touch. It will bring together research in Human-Computer Interaction on intimate technologies with new interaction techniques, alongside psychological theories on intimacy and neuroscience perspectives on touch. Technologies that touch us will constitute a new paradigm of interactive devices, most strongly exemplified by care robots. Designing technologies for Intimate Touch will be foundational in creating dignified and acceptable interactions between humans and technologies.  The first objective is to develop a model of ‘intimate technology’. No researcher has done this before. This model will be developed through a large-scale interview study alongside in-situ, long-term studies of our own demonstrators of Intimate Touch. By identifying which interactions lead to intimacy, this project will have empirically identified a new class of technology, ‘intimate technology’. Autonomous systems will touch many areas of our bodies. Yet, there has been no serious study of touch experiences other than on the hands and shoulders. My second objective will counter this by innovating on a design approach that centres the felt experience of touch from technology, and by creating a dataset that describes people’s experience of touch from technology across the body. My final objective is to develop two demonstrators of Intimate Touch. This risky challenge will evidence how touch with technology transforms us. Practically this will provide a roadmap to good touch from technology. Empirically this will lay the groundwork for a re-conceptualization of our relationship with technology

Mots-clés : research through design,intimacy,touch,body,soma design,interdisciplinary research
Projet ERC : MeMoSA (Horizon Europe, appel 2023, Consolidator grants)
Domaine scientifique : Life Science
Panel : Prevention,  Diagnosis and T reatment of Human Diseases
Entité participante : Université de Gand — Pays : Belgique — Rôle : PI
Acronyme de l'entité : UGent
Type d'entité : Enseignement supérieur ou secondaire
Financement ERC de l'entité : 1999763.0 €

While recent advent empowered the new reality of holistic metabolic phenotyping, we are currently still unable to accurately determine the source(s) of the underlying metabolites. This is undoubtedly the main stumbling block in inferring causality to new biomarkers for disease prevention, prediction, and prognosis, particularly given the rapidly increasing burden of metabolic diseases. At the same time, conventional metabolomics methods do not meet the requirements for adoption in clinical practice. MeMoSA will address these issues by unraveling the source hierarchy of the gastrointestinal metabolome, ultimately enabling effective personalized treatments through longitudinal source modulation and follow-up. First, two workflows for 1. high-throughput comprehensive 2D metabolomics and lipidomics and, 2. rapid clinically applicable ambient ionization metabotyping, will be developed. Second, molecular fingerprints of our unique deeply phenotyped pediatric cohorts (1.5k children) will be generated and advanced machine learning algorithms will be used to predict metabolite abundances based on their sources, i.e., diet, lifestyle, anthropometrics, microbiome, drug intake, psychological factors, clinical markers, etc. Third, a combination of in vitro digestions, in vivo humanized mice, and in silico experiments with selected source variables will be designed to contribute to our understanding of source-metabolite causality. These mechanistic insights will be used to build dedicated intervention trials in children with specific source-dominated metabotypes. MeMoSA will lay the foundation for integrating metabolomics into personalized and preventive medicine in children through (i) better prediction of individual metabotypes in relation to health; (ii) in-depth insight into metabolite sources, which will foster a framework for biomarker qualification and unraveling disease etiology; (iii) greater treatment efficacy through dedicated metabolome-driven source modulation.

Mots-clés : metabotyping,mass spectrometry,pediatrics,4p medicine
Projet ERC : BIGDATPOL (Horizon Europe, appel 2022, Consolidator grants)
Domaine scientifique : Social Sciences and Humanities
Panel : Institutions, Governance and Legal Systems
Entité participante : Université de Gand — Pays : Belgique — Rôle : PI
Acronyme de l'entité : UGent
Type d'entité : Enseignement supérieur ou secondaire
Financement ERC de l'entité : 1972500.0 €

Big data policing is an innovative strategy that uses historical data to forecast when and where there is a high risk of new crime events in order to use police resources more efficiently and proactively, and ultimately reduce crime rates. Big data policing models can consist of variables based on crime data available in police databases (e.g. previous crime events), socio-economic data (e.g. poverty index, residential mobility), opportunity characteristics (e.g. the presence of shops, distance to nearest highway), data from new technologies (e.g. intelligent cameras) and other known predictors of crime (e.g. police patrol intensity).  However, there are several research gaps that need to be addressed. First, knowledge about and expertise in big data policing in Europe is currently fragmented. Second, there is a lack of interdisciplinarity with regard to big data policing studies, and yet the involvement of several disciplines is required when studying the issue. Third, there is a lack of scientific evaluations of big data policing models.  The overarching objective of this ERC project is to unite and integrate the statistical-methodological, criminological, legal and ethical dimensions of big data policing in an evidence-based model that will be tested by different randomized controlled trials and built on the principles of an international (i.e. European) and interdisciplinary approach. The latter aim should be enabled by incorporating and conducting different PhD tracks focusing on these specific dimensions, which should allow better knowledge, insights and understanding of big data policing to be developed. This approach is innovative and radically different from the existing commercial and economic initiatives, which lack transparency on their predictive reliability and validity, effectiveness and legal and ethical safeguards.

Mots-clés : big data policing predictive policing spatiotemporal criminology crime statistics crime mapping governance law enforcement statistics methodology ethical responsibility randomized controlled trials intelligence led policing
Projet ERC : CLEVeR (Horizon Europe, appel 2021, Consolidator grants)
Domaine scientifique : Physical Sciences and Engineering
Panel : Universe Sciences
Entité participante : European Southern Observatory — Pays : Allemagne — Rôle : PI
Acronyme de l'entité : ESO
Type d'entité : Recherche
Financement ERC de l'entité : 693750.0 €

Galaxy groups play a crucial role in modern cosmology by providing the key test for the predictions of models of large-scale structure and galaxy formation and evolution. This is because their hot gas content, and thus their X-ray appearance, is determined by the fundamental ingredient of the modern cosmological models, i.e. the feedback of the supermassive black hole hosted by the central galaxy. However, differently from galaxy clusters, within this general framework, the predictions of the galaxy group baryonic content very vastly depend on the feedback implementation. For this reason, they are the ideal laboratory to provide the ultimate constraint for anchoring the simulations. At present, there are no observational constraints to guide the theory and to discern among the different scenarios. The aim of the present proposal is to fill this fundamental gap in our understanding by characterizing the galaxy group population in terms of baryonic content, from their hot gas on Mpc scale to their galaxy population properties on kpc scale. The main limitation to doing so, thus far, has been the lack of X-ray observations of galaxy groups, due to the low sensitivities of previous surveys. With CLEVeR we will overcome this by taking advantage of the unprecedented statistics and sensitivity at the group mass scale of the eROSITA All Sky Survey in the X-rays. In addition, we will complement eROSITA data with upcoming 4MOST spectroscopic surveys of galaxy groups in the optical and with ancillary datasets that capture specific physical processes of the feedback and the central galaxy itself, such as MaNGA, MUSE, and LOFAR. With such an ultimate dataset, we will, then, be able to study and constrain all relevant components on all relevant scales to nail down the physics of galaxy groups and of their interaction with black hole feedback and, from there, of the large-scale structure simulations of the Universe.

Mots-clés : galaxy groups intra group and intra cluster medium black hole feedback gas cooling black hole feedback interplay
Projet ERC : MAMBA (Horizon Europe, appel 2021, Consolidator grants)
Domaine scientifique : Social Sciences and Humanities
Panel : The Study of the Human Past
Entité participante : Leibniz-Gemeinschaft — Pays : Allemagne — Rôle : Partner
Acronyme de l'entité : WLG
Type d'entité : Autres
Financement ERC de l'entité : 84750.0 €

The discovery of large accumulations of woolly mammoth remains together with Upper Palaeolithic artefacts has fascinated both researchers and the general public since the 19th century. Despite many years of scientific research and dispute our knowledge about these sites and the relationship between mammoths and contemporaneous Upper Palaeolithic hunter-gatherers remains incomplete. This project focuses on the mammoth bone accumulations found in the West Carpathian forelands and seeks to establish why they formed and their function for hunter-gatherer groups 35,000-25,000 years ago – a period of major techno-cultural and environmental change in approaching the Last Glacial Maximum. For the first time we will study materials covering the full chronological range of this archaeological phenomenon, considering both existing collections alongside new fieldwork at the key sites of Dolní Věstonice I, Kraków Spadzista and Langmannersdorf. Site-specific signals of human-mammoth interaction within their local palaeoenvironmental context will be used to investigate chrono-spatial changes in both mammoth populations and hunter-gatherer societies. We will employ standardised field and laboratory protocols that utilise recent methodological and technological advances in ancient DNA research, stable isotope studies, radiometric dating, palaeoenvironmental reconstruction and palaeodemographic modelling. The resulting dataset will allow an integrated investigation of the formation of mammoth bone accumulations and produce a statistically analysable dataset expected to reveal the interactions between human and mammoth populations in Central Europe in the context of palaeoenvironmental changes. This will have great impact not only for Upper Palaeolithic research in Central Europe, but will on a general scale also contribute to an improved understanding of human behaviour, cultural developments, and human adaptation to dynamically changing climatic and environmental conditions.

Mots-clés : upper palaeolithic,pleistocene
Projet ERC : geNEOMORPH (Horizon Europe, appel 2024, Consolidator grants)
Domaine scientifique : Life Science
Panel : Prevention,  Diagnosis and T reatment of Human Diseases
Entité participante : Aithyra gmbh research institute for biomedical artificial intelligence of the austrian academy of sciences — Pays : Autriche — Rôle : PI
Acronyme de l'entité : AITHYRA
Type d'entité : Organismes privés (hors enseignement)
Financement ERC de l'entité : 1999724.0 €

Many cancers are driven by mutations affecting transcription regulation. Through cancer genome sequencing studies, we understand that these aberrations are pervasive through many layers of gene control. Yet, with few exceptions, this knowledge has not precipitated in effective treatments since pharmacologic inhibition of transcription is often infeasible or functionally inconsequential.  To address this limitation, I want to innovate chemical strategies that move beyond loss of function (LOF) approaches. Gene control is organized at the level of proximity. Hence, I hypothesize that transcriptional regulators can be chemically rewired by neomorphic small molecules that recruit functionally opposing gene-regulatory effectors, thereby prompting an acute, deep, and sustained disruption of oncogenic transcriptional circuits. The identification, characterization, and translation of such Neomorphic Transcriptional Compounds (NeoTraCs) will be the subject of the GE|NEomorph proposal. We will focus on NeoTraCs to rewire the repressive PRC2 complex, the p400 chromatin regulator complex, and the non-canonical BAF complex. While these targets have established roles in various cancers, inhibitors are not available or have limited functional impact.  To identify NeoTraCs that address these limitations, we will implement a diverse discovery approach that incorporates hypothesis-driven design with phenotypic strategies geared to co-opt undrugged transcriptional effectors via bivalent NeoTraCs, and unligandable effectors via molecular glue-like NeoTraCs. Identified hits will be characterized via multi-omics approaches. Through careful mechanistic investigation, we will deduce general mechanistic principles, understand their impact on oncogenic transcription and investigate associated translational opportunities.  GE|NEomorph will significantly advance our ability to understand and disrupt transcriptional dysregulation in cancer and pave the way for novel innovative therapies.

Mots-clés : proximity inducing pharmacology,chemical genetics,chemical proteomics,transcription,target identification
Projet ERC : MICROBE (Horizon Europe, appel 2021, Consolidator grants)
Domaine scientifique : Life Science
Panel : Prevention,  Diagnosis and T reatment of Human Diseases
Entité participante : Université de Gand — Pays : Belgique — Rôle : PI
Acronyme de l'entité : UGent
Type d'entité : Enseignement supérieur ou secondaire
Financement ERC de l'entité : 2000000.0 €

Emerging evidence from cancer patients and mouse models indicates that gut bacteria affect response to immune checkpoint inhibitors (ICI). As a result, modification of gut bacteria by dietary changes, probiotics and fecal transplantations are explored but a huge gap remains to gain clinical application. Limiting factors are the lack of mechanistic knowledge on how gut bacteria impact ICI response, the need of antibiotics to treat infections in cancer patients and gut resilience to exogenous bacterial colonization. Bacteria release nanometer-sized extracellular vesicles (BEV), loaded with specific pathogen-associated molecular patterns (PAMP), which possess multiple favorable characteristics for clinical application but remain minimally explored in oncology. Recently, my research group pioneered the discovery of gut-derived immunomodulatory BEV in the systemic circulation (sysBEV) of non-septicemic cancer patients. I hypothesize that sysBEV direct ICI response by initiating cytokine release to instruct innate and adaptive anti-tumor immunity. The overall scientific objective of my ERC-CoG project is to establish an innovative nanotherapeutic strategy using non-replicating BEV nanoparticles as a game changer to establish a safe but potent and durable ICI response. Hereto, MICROBE will analyze cancer patient biospecimens to address a number of fundamental questions with regard to BEV characteristics that are essential to ICI response and implement this know-how to formulate BEV nanotherapeutics from gut bacteria of healthy donors and ICI responsive cancer patients. The optimal administration route, treatment dosage, pharmaco-kinetics and -dynamics will be established and the synergism between BEV nanotherapeutics and ICI will be elucidated using clinically relevant mouse models. In conclusion, MICROBE will provide the EU a frontrunner position for a future first-in-human clinical trial using BEV nanotherapeutics in anti-cancer treatment.

Mots-clés : extracellular vesicles,bacterial extracellular vesicles,outer membrane vesicles
Projet ERC : BREAKFREE-Sy (Horizon Europe, appel 2024, Consolidator grants)
Domaine scientifique : Life Science
Panel : Prevention,  Diagnosis and T reatment of Human Diseases
Entité participante : Université de Washington — Pays : Etats-Unis — Rôle : Partner
Acronyme de l'entité : UW
Type d'entité : Enseignement supérieur ou secondaire
Financement ERC de l'entité : 925000.0 €

For over 50 years, the tools for diagnosing, preventing, and treating syphilis have seen minimal progress, partly due to limitations in bacterial cultivation. Existing tools were primarily drawn from research on early-stage syphilis and evidence extrapolated to severe forms of the infection, leaving important unmet needs like the lack of predictive markers for neurosyphilis and mother-to-child-transmission, limited evidence on treatments for these conditions, and challenges in monitoring treatment failure. This project aims to shift the paradigm by demonstrating that the diverse manifestations of syphilis are not merely random infections in different bodily compartments but are intricately linked to unique bacterial traits and host responses that necessitate specific tools. Our goal is to discover manifestation-specific biomarkers, repurpose antibiotics for tailored treatments, and pioneering TPA isolation methods for treatment monitoring. Taking advantage of a unique network of collaborators in areas with a high incidence of severe syphilis, I will examine how severe clinical manifestations relate to genomic variations in TPA strains and with host humoral responses. A groundbreaking pan-proteomic array will allow identifying markers linked to clinical phenotypes and it will open avenues for discovery of new antigens as vaccine candidates. Furthermore, I will exploit the established expertise of my team on drug repurposing and conducting randomized clinical trials to evaluate the efficacy of alternative antibiotics to cure patients with neurosyphilis and syphilis in pregnancy. Finally, I aim to pioneer methods for the first-time isolation of TPA from patient samples and conduct antimicrobial resistance testing in treatment failures. The resulting tools will be a tremendous resource for preventing adverse outcomes like neurological sequelae, stillbirth, congenital syphilis and treatment failure, especially in low-middle-income countries where most complications occur

Mots-clés : neurosyphilis strains,treponema neuroinvasive adhesin,treponema circulating strains genome,treponema deep proteome,congenital syphilis in the pacific,antibiotic resistant treponema pallidum treponema outer membrane proteins,
Projet ERC : BREAKFREE-Sy (Horizon Europe, appel 2024, Consolidator grants)
Domaine scientifique : Life Science
Panel : Prevention,  Diagnosis and T reatment of Human Diseases
Entité participante : Hospital (institute) for skin diseases, chinese academy of medical sciences — Pays : Chine — Rôle : Partner
Type d'entité : Recherche
Financement ERC de l'entité : 594029.5 €

For over 50 years, the tools for diagnosing, preventing, and treating syphilis have seen minimal progress, partly due to limitations in bacterial cultivation. Existing tools were primarily drawn from research on early-stage syphilis and evidence extrapolated to severe forms of the infection, leaving important unmet needs like the lack of predictive markers for neurosyphilis and mother-to-child-transmission, limited evidence on treatments for these conditions, and challenges in monitoring treatment failure. This project aims to shift the paradigm by demonstrating that the diverse manifestations of syphilis are not merely random infections in different bodily compartments but are intricately linked to unique bacterial traits and host responses that necessitate specific tools. Our goal is to discover manifestation-specific biomarkers, repurpose antibiotics for tailored treatments, and pioneering TPA isolation methods for treatment monitoring. Taking advantage of a unique network of collaborators in areas with a high incidence of severe syphilis, I will examine how severe clinical manifestations relate to genomic variations in TPA strains and with host humoral responses. A groundbreaking pan-proteomic array will allow identifying markers linked to clinical phenotypes and it will open avenues for discovery of new antigens as vaccine candidates. Furthermore, I will exploit the established expertise of my team on drug repurposing and conducting randomized clinical trials to evaluate the efficacy of alternative antibiotics to cure patients with neurosyphilis and syphilis in pregnancy. Finally, I aim to pioneer methods for the first-time isolation of TPA from patient samples and conduct antimicrobial resistance testing in treatment failures. The resulting tools will be a tremendous resource for preventing adverse outcomes like neurological sequelae, stillbirth, congenital syphilis and treatment failure, especially in low-middle-income countries where most complications occur

Mots-clés : neurosyphilis strains,treponema neuroinvasive adhesin,treponema circulating strains genome,treponema deep proteome,congenital syphilis in the pacific,antibiotic resistant treponema pallidum treponema outer membrane proteins,